Key result
In the presence of thrombopoietin, Epigallocatechin-3-gallate (10-100 nM) promoted a 1.5-fold increase in CFU-Meg-derived colony formations from human CD34+ cells compared with control.
Why the study?
Does Epigallocatechin-3-gallate (EGCg) promote the proliferation and differentiation of human megakaryocytic progenitor cells?
Does Epigallocatechin-3-gallate (EGCg) promote the proliferation and differentiation of human megakaryocytic progenitor cells?
Effect estimate: 1.5-fold increase
EGCg promotes megakaryocytopoiesis and thrombopoiesis in ex vivo cultures of CD34+ cells, suggesting potential protective effects against radiation damage.
Epigallocatechin-3-gallate (EGCg) has been widely recognized as a powerful antioxidant and free radical scavenger. The effects of EGCg on the proliferation and differentiation of X-irradiated megakaryocytic progenitor cells (colony-forming unit-megakaryocyte, CFU-Meg) using CD34+ cells prepared from human placental and umbilical cord blood have been shown. In the absence of exogenous thrombopoietin (TPO), no colonies are observed in cultures containing or lacking EGCg (1 nM-100 microM). In the presence of TPO, in contrast, EGCg significantly promotes CFU-Meg-derived colony formations within the 10-100-nM range. A 1.5-fold increase in the total number of CFU-Meg has been counted compared with the control. These favorable effects of EGCg are also observed in the culture of CD34+ cells before and after X irradiation with 2 Gy. Moreover, in order to investigate the function of EGCg promoting megakaryocytopoiesis and thrombopoiesis in ex vivo cultures, both non-irradiated and X-irradiated CD34+ cells are grown in liquid cultures supplemented with TPO. In both cultures, EGCg increases the total number of cells and megakaryocytes. It has been suggested that the favorable effects of EGCg reduce the risk factor from radiation damage in megakaryocytopoiesis.
No takes yet. Share an insight, caveat, or question.
Monzen et al. (2006) studied Radiation damage in megakaryocytopoiesis. Epigallocatechin-3-gallate (EGCg) vs. Control (cultures lacking EGCg) was evaluated on CFU-Meg-derived colony formations (1.5-fold increase). In the presence of thrombopoietin, Epigallocatechin-3-gallate (10-100 nM) promoted a 1.5-fold increase in CFU-Meg-derived colony formations from human CD34+ cells compared with control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: